The Synovial Signature and Response to Biologics-A step towards Personalized Medicine in Refractory Rheumatoid Arthritis

Reem Hamdy A Mohammed
Department of Rheumatology and Rehabilitation, Cairo University, Egypt

Corresponding author: Reem Hamdy A Mohammed, Department of Rheumatology and Rehabilitation, Cairo University, Egypt, Tel. 966501208020; E-mail: rmhamdy@yahoo.com

Received date: June 22, 2015; Accepted date: June 23, 2015; Published date: June 30, 2015

Copyright: © 2015 Mohammed RHA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Rheumatoid Arthritis is a multi-system autoimmune disease in which symmetrical joint inflammation, hyperplasia of the synovium, and formation of invasive granulation tissue (pannus) stand out as distinctive disease features. The advancing disease process eventually proceeds to joint destruction with deformity and persistent disability [1-3]. Throughout its’ history the disease have displayed a complex heterogeneity in both disease course and patient response to therapy. Clinical response depends on disease state and disease characteristics indeed there are different subtypes of RA with different genetic backgrounds that interpret into benign or destructive, seropositive versus seronegative RA.

With the widespread implementation of the biologic strategy, rheumatologists have experienced a victorious shift that has undoubtedly improved the disease outcome with up to 65-70% of the treated patients achieving either remission or low disease activity. However, with autoimmune diseases one should always expect the unexpected, despite their reported efficacy in refractory rheumatoid arthritis (RA), still a proportion of patients ranging from 20-40% display poor/no response to their first line biologic DMARDs therapy. A part of this variability might be due to drug concentration and pharmacokinetic which is influenced by the characteristics of the patient such as age, gender, renal and liver functions, body mass index (BMI), or smoking status, as well as disease status and disease characteristics. Concomitant use of synthetic DMARDS might additionally affect drug concentrations [4-10].

The rationales behind the primary failure of biologics remain poorly understood with a number of recent researches and trials assigning primary drug failure to a number of factors referred to as predictors of response to biologic therapy.

Amongst these predictors the most recently investigated point in the field was the impact of cytogenetic markers within the synovium to the response to such therapy which can be described as the “synovial signature”. Different studies have evaluated the contribution of synovial phenotypes and local cellular aggregates to the in-situ cytokine profile which might presumably affect response to therapy. In one study by Klaasen et al. [10], lymphocytic synovial aggregates favored a good response in RA. In another late trial by Dennis et al. [11], the investigators reported four major phenotypes of RA synovium the lymphoid, the myeloid, the low inflammatory and fibroid phenotypes. Each phenotype displayed a distinctive underlining gene signature, with the study revealing that the synovial myeloid but not the lymphoid favored a good EULAR response with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 43: 1670-1673.

Kristensen LE, Kapetanovic MC, Gulfe A, Geborek P (2008) Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 47: 4939.

Kleinert S, Tony H, Krause A, Feuchtenberger M, Wassenberg S, Richter C et al. (2012) Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis data from a German non-interventional observational study, Rheumatol Int 32: 2759-2767.

Klaasen R, Thurlings RM, Vrijbrandts CA, van Kuijk AW, Baeten D, et al. (2009) The relationship between synovial lymphocyte aggregates and the adhesion ICAM-1 which displayed the most robust response to TNF-1, whereas the lymphoid genotype was associated with higher serum C-X-C motif chemokine 13 (CXCL-13) showing a poor response [11,12]. This study highlighted the extreme importance of synovial gene expression and emphasized the hypotheses that synovial phenotypic variations “Synovial Signature” might to a great extent affect serum cytogenetic biomarkers and thereby affecting disease expression and response to therapy [10-12].

The deeper we investigate the better the recognition of such cellular and molecular variants and the more successful we apply the treat to target strategy, a novel approach towards “Personalized Medicine” in refractory disease.

References

1. Burmester GR, Pratt AG, Scherer HU, Van-Laar JM (2012) Rheumatoid Arthritis: pathogenesis and clinical features. In EULAR textbook on Rheumatic Diseases, Editor: Johannes WJ Bijlsma. Elsevier, Saunders 206-231.
2. Goronzy JJ, Weyand CM (2005) Rheumatoid arthritis. Immunol Rev 204: 55-73.
3. Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358: 903-911.
4. Mohammed RHA, Farahat F, Kewan HH, Bukhari M (2015) Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease. Springerplus-Rheumatology collection 4: 207.
5. Mohammed RH, Kewan HH, Bukhari M (2014) Assessment of the treat-to-target strategy in patients with refractory rheumatoid arthritis. A prospective study on efficacy and safety in a Saudi population. Z Rheumatol 73: 746-753.
6. Hyrich KL, Watson KD, Silman AJ, Symmons DPM (2006) Predictors of response to anti-TNF-therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 45: 15865.
7. Mancarella L, Bobbio-Pallavicini F, Cecarelli F, Falangone PC, Ferrante A, et al. (2007) Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEAR study. J Rheumatol 34: 1670-1673.
8. Kristensen LE, Kapetanovic MC, Gulfe A, Geborek P (2008) Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 47: 4939.
9. Kleinert S, Tony H, Krause A, Feuchtenberger M, Wassenberg S, Richter C et al. (2012) Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis data from a German non-interventional observational study, Rheumatol Int 32: 2759-2767.
10. Klaasen R, Thurlings RM, Vrijbrandts CA, van Kuijk AW, Baeten D, et al. (2009) The relationship between synovial lymphocyte aggregates and the
clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum 60: 3217-3224.

11. Tak PP, Bresnihan B (2000) The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 43: 2619-2633.

12. Dennis G Jr, Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, et al. (2014) Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther 16: R90.